ViiV’s fostemsavir shows promise in ‘heavily pre-treated’ HIV patients
ViiV Healthcare’s first-in-class attachment inhibitor fostemsavir has shown promise as a treatment for heavily pre-treated HIV patients failing on current antiretroviral regimens.
Read More
